Enhancing anti-CTLA-4 antibody delivery to the brain using focused ultrasound and microbubbles
File(s)
Author(s)
Pereira, Maria Afonso
Drevenakova, Vanessa
Liu, Qiyixing Ethan
Grewal, Sarina
Morse, Sophie V
Type
Journal Article
Abstract
Introduction
Gliomas, particularly glioblastomas, are characterised by their poor prognosis and low patient survival rate. Cytotoxic T lymphocyte-associated antigen-4 antibodies, a type of immune checkpoint inhibitors, have shown promise as an effective treatment strategy against the most aggressive tumour cells within the microenvironment of gliomas. However, their delivery to the brain is hindered by the impermeable blood-brain barrier, which is leaky in a heterogenous way, leading to uneven drug distribution across the tumours. Focused ultrasound, combined with intravenously administered microbubbles, is a technique that can non-invasively, safely, and reversibly increase the permeability of the blood-brain barrier in a targeted area, promoting the delivery of therapeutics, such as immune checkpoint inhibitors, to inaccessible tumour areas, to prevent tumour relapse.
Methods
We applied two different types of focused ultrasound sequences (long pulses vs rapid short-pulses) with microbubbles to the left hippocampus of wild-type female C57BL/6 mice before administering a fluorescently labelled cytotoxic T lymphocyte-associated antigen-4 antibody.
Results
We determined that the targeted brain region had a significant (p < 0.0001) increase in antibody delivery following ultrasound treatment with both pulse sequences. A more uniform delivery was achieved when treating with rapid short-pulse sequences, where bursts of short 5 µs pulses of focused ultrasound were emitted at a fast repetition frequency (1.25 kHz). We observed a significant increase in anti-tumour immune cells in long-pulse treated brains.
Conclusion
These results provide a proof-of-principle for how focused ultrasound with microbubbles can promote homogenous anti-tumour drug delivery and modulate the immune microenvironment.
Gliomas, particularly glioblastomas, are characterised by their poor prognosis and low patient survival rate. Cytotoxic T lymphocyte-associated antigen-4 antibodies, a type of immune checkpoint inhibitors, have shown promise as an effective treatment strategy against the most aggressive tumour cells within the microenvironment of gliomas. However, their delivery to the brain is hindered by the impermeable blood-brain barrier, which is leaky in a heterogenous way, leading to uneven drug distribution across the tumours. Focused ultrasound, combined with intravenously administered microbubbles, is a technique that can non-invasively, safely, and reversibly increase the permeability of the blood-brain barrier in a targeted area, promoting the delivery of therapeutics, such as immune checkpoint inhibitors, to inaccessible tumour areas, to prevent tumour relapse.
Methods
We applied two different types of focused ultrasound sequences (long pulses vs rapid short-pulses) with microbubbles to the left hippocampus of wild-type female C57BL/6 mice before administering a fluorescently labelled cytotoxic T lymphocyte-associated antigen-4 antibody.
Results
We determined that the targeted brain region had a significant (p < 0.0001) increase in antibody delivery following ultrasound treatment with both pulse sequences. A more uniform delivery was achieved when treating with rapid short-pulse sequences, where bursts of short 5 µs pulses of focused ultrasound were emitted at a fast repetition frequency (1.25 kHz). We observed a significant increase in anti-tumour immune cells in long-pulse treated brains.
Conclusion
These results provide a proof-of-principle for how focused ultrasound with microbubbles can promote homogenous anti-tumour drug delivery and modulate the immune microenvironment.
Date Acceptance
2026-01-06
Citation
ImmunoTargets and Therapy
ISSN
2253-1556
Publisher
Dove Medical Press
Journal / Book Title
ImmunoTargets and Therapy
Copyright Statement
Copyright This paper is embargoed until publication. Once published the Version of Record (VoR) will be available on immediate open access.
License URL
Publication Status
Accepted